<div>
  <ul>
    <li>
      <p>
        AI-based cell therapy company Modulus Therapeutics has sold its cell therapy platform assets to cell programming and biosecurity company Ginkgo Bioworks for an undisclosed sum.
      </p>
    </li>
    <li>
      <p>
        The acquisition will incorporate Modulus' CAR and switch receptor designs and libraries into Ginkgo's existing cell therapy services to assist customers in the advancement of the performance of T-cell- and NK-cell-based CAR therapies.&nbsp;
      </p>
    </li>
  </ul>
  <p>
  </p>
</div>


<div>
  <p>
    <a href="https://www.prnewswire.com/news-releases/ginkgo-bioworks-acquires-modulus-therapeutics-cell-therapy-assets-to-strengthen-next-gen-car-designs-302105056.html">
      Press release
    </a>
  </p>
  <p>
    <a href="https://markets.businessinsider.com/news/stocks/ginkgo-bioworks-acquires-modulus-therapeutics-cell-therapy-platform-assets-1033214384">
      Marker Business Insider
    </a>
  </p>
  <p>
  </p>
  <p>
    <b></b>
  </p>
</div>


Cell & Gene Therapy

<div>
 <p>Modulus Therapeutics, a firm that uses artificial intelligence in cell therapy, has sold its cell therapy platform assets to a cell programming and biosecurity company, Ginkgo Bioworks. The specific financial details of the deal were not disclosed.</p>
 <p>Ginkgo plans to integrate Modulus' CAR and switch receptor designs and libraries into its own services. This incorporation will support Ginkgo's customers in developing and improving the performance of T-cell- and NK-cell-based CAR therapies.</p>
</div>

Modulus Therapeutics sells cell therapy platform to Ginkgo Bioworks for undisclosed amount

A new wave of meat, fish, and poultry alternatives are driving this hyper-growth industry into the mainstream.

Plant-based Meat

ANALYST_QUICK_TAKE

PROMINENT_CATEGORY

<div>
 <p>AQUA Cultured Foods, is a company that develops fish-free seafood via microbial fermentation. Recently, AQUA has decided to join forces with Ginkgo Bioworks, a company known for its cell programming and biosecurity services. The goal of this partnership is to enhance AQUA's fermentation technology and product output. </p>
 <p>Ginkgo will use its knowledge and expertise in microbial analysis to further refine and standardize AQUA's unique strains and processes, which are crucial for consistently creating high-quality alternative seafood offerings. As part of their collaboration, the two companies are planning to create innovative products for the wider food industry. </p>
</div> <p><b>Analyst QuickTake:<br>
 </b> In its most recent funding round, AQUA Cultured Foods raised <a href="https:<br>
//sp-edge.com/updates/17570"> USD 5.5 million </a> in seed funding to expand partnerships and facilitate product launches. The company has held <a href="https:<br>
//sp-edge.com/updates/17282"> tastings </a> for its alternative seafood but has yet to launch a product commercially. This partnership will help the company to enhance its production and expedite its go-to-market efforts.</p>

AQUA Cultured Foods partners with Ginkgo Bioworks to bolster alternative seafood production

A booming food and beverage segment with a history as rich and varied as its present-day product offerings.

Plant-based Dairy & Egg

<div>
 <p>Imagindairy, an Israeli Food Tech company, has formed a partnership with Ginkgo Bioworks, a company specializing in cell programming and biosecurity, to develop and produce dairy proteins that do not require the use of animals or whey products. There is an economic focus for their production plan.</p>
 <p>This partnership will take place over multiple years and is partially sponsored by a shared grant from the Israel-US Binational Industrial Research and Development (BIRD) Foundation. The collaboration will use Ginkgo’s protein expression services and Imagindairy's development skills at scaling up production processes. The aim is to develop optimized organisms that can cost-effectively produce non-whey dairy proteins.</p>
 
</div> <p><b>Analyst QuickTake:<br>
 </b> Recently, Imagindairy <a href="https:<br>
//sp-edge.com/updates/25649"> acquired </a> industrial-scale production lines that can process over 100,000 liters of precision-fermented dairy proteins, with plans to triple this capacity over the next two years. This increased capacity will likely help to reduce production costs by providing economies of scale.</p>

Imagindairy partners with Ginkgo Bioworks to produce cost-effective, animal-free, non-whey dairy proteins

Artificial intelligence is identifying and testing new therapies faster than ever.

AI Drug Discovery

<div>
 <p>Swiss AI biotech startup Cradle has teamed up with Ginkgo Bioworks, a cell programming and biosecurity firm, in a collaborative agreement aimed at providing a platform for research and development teams to pursue advanced protein design. The specifics and financial aspects of the deal remain undisclosed.</p>
 <p>This collaboration will incorporate Cradle's generative machine-learning algorithms into Ginkgo’s technology enabling enhanced protein design, increased productivity, and faster progress in experimental rounds in various sectors such as pharmaceuticals, food, and specialty chemicals.</p>

</div>

Cradle partners with Ginkgo Bioworks to advance protein engineering through AI

Empowering Tomorrow's Innovations with Generative AI Infrastructure

Generative AI Infrastructure

<div>
 
 <p>Reverie Labs, an AI drug discovery company, has sold its crucial assets to Ginkgo Bioworks, a cell programming and biosecurity company. The cost of the acquisition has not been disclosed. </p>
 <p>This acquisition will enable Ginkgo Bioworks to incorporate Reverie's systems such as models, software, and workflows into their own system. This will enhance Ginkgo’s capabilities in AI/ML for experimental design and support its small molecule programs. Moreover, Ginkgo will use the Reverie Labs assets to augment its AI/ML-based discovery services. </p>
 
</div>

Reverie Labs sells key AI drug discovery assets to Ginkgo Bioworks for undisclosed sum

<div>

 <p>Reverie Labs, a firm specializing in AI drug discovery, has offloaded its primary assets to biosecurity and cell programming enterprise Ginkgo Bioworks in a confidential deal. </p>
 <p>As part of the deal, Ginkgo is set to integrate Reverie's workflows, software, and models into its own system, thus enhancing its AI/ML capabilities in relation to experimental design. This will also assist its programs linked to small molecule. The assets from Reverie Labs will be employed by Ginkgo to enhance its AI/ML-based discovery services. </p>

</div>

Empowering sustainable food innovation through food engineering tech

Novel Foods

<div>

<p>Phytolon and Ginkgo Bioworks, a biotech firm and biosecurity platform respectively, have completed the initial phase of their joint project targeting the production of natural food colors. The project utilises engineered yeast strains to create betalain pigments through fermentation, which can produce colors from yellow to purple, reds, pinks, and oranges. This process provides a sustainable, cost-effective alternative to artificial food dyes.</p>

</div> <p><b>Analyst QuickTake: </b> The Phytolon and Ginkgo Bioworks partnership was formed in 2022 to leverage Ginkgo's biological engineering capabilities for yeast fermentation-based food color production. With California <a href="https://edition.cnn.com/2023/10/09/health/california-governor-bans-red-dye-no-3-wellness/index.html"> banning </a> Red dye no. 3 and increasing scrutiny around synthetic food colorants, this partnership has the potential and opportunity to provide natural solutions to the global food industry.</p>

Phytolon and Ginkgo Bioworks complete first milestone for natural food colors

The Dutch company Vivici has collaborated with Ginkgo Bioworks to enhance and market functional alternative proteins. Ginkgo will utilize their expertise in strain engineering to screen, validate, and deliver optimized strains for dairy protein production through precision fermentation.

Vivici partners with Ginkgo Bioworks to advance sustainable dairy protein production

Tech solutions for achieving global anti-wastage targets

Food Waste

DISRUPTOR_PRESENT

<p>Ginkgo Bioworks, a platform specializing in cell programming and biosecurity, has partnered with dairy cooperative Foremost Farms USA to manufacture environmentally friendly materials derived from dairy co-products.</p><p>The partnership aims to use biotechnology to convert low-value dairy co-products into environmentally friendly materials. This process aims to reduce the carbon footprint of the dairy industry while also potentially creating a new revenue stream for dairy farmers.</p>

Ginkgo Bioworks and Foremost Farms partner to develop cycling dairy products technology

<div>
 
 <ul>
  <li><p>QL AG, a Switzerland-based FoodTech company, has partnered with Ginkgo Bioworks, a biotechnology firm, to develop animal-free dairy proteins using precision fermentation.</p></li>
  <li><p>Through the partnership, QL AG will leverage Ginkgo's expertise in strain engineering and protein production to reduce costs, improve taste and texture, and produce alternative dairy products that are nutritionally equivalent to traditional dairy products.&nbsp;</p></li>
  <li><p>Founded in 2022, QL AG leverages high-throughput screening research technology to develop microorganisms capable of producing milk proteins. The company claims its development process is significantly faster than others and bases its research on goat milk proteins rather than cow milk proteins.</p></li>
 </ul>
 
</div> 

QL AG, a Switzerland-based FoodTech company, has partnered with Ginkgo Bioworks, a biotechnology firm, to develop animal-free dairy proteins using precision fermentation. Through the partnership, QL AG will leverage Ginkgo's expertise in strain engineering and protein production to reduce costs, improve taste and texture, and produce alternative dairy products that are nutritionally equivalent to traditional dairy products. Founded in 2022, QL AG leverages high-throughput screening research technology to develop microorganisms capable of producing milk proteins. The company claims its development process is significantly faster than others and bases its research on goat milk proteins rather than cow milk proteins.

All Updates

Modulus Therapeutics sells cell therapy platform to Ginkgo Bioworks for undisclosed amount

AQUA Cultured Foods partners with Ginkgo Bioworks to bolster alternative seafood production

Imagindairy partners with Ginkgo Bioworks to produce cost-effective, animal-free, non-whey dairy proteins

Cradle partners with Ginkgo Bioworks to advance protein engineering through AI

Reverie Labs sells key AI drug discovery assets to Ginkgo Bioworks for undisclosed sum

Reverie Labs sells key AI drug discovery assets to Ginkgo Bioworks for undisclosed sum

Phytolon and Ginkgo Bioworks complete first milestone for natural food colors

Vivici partners with Ginkgo Bioworks to advance sustainable dairy protein production

Ginkgo Bioworks and Foremost Farms partner to develop cycling dairy products technology

QL AG partners with Ginkgo Bioworks to develop precision-fermented dairy proteins

Cell & Gene Therapy

Modulus Therapeutics sells cell therapy platform to Ginkgo Bioworks for undisclosed amount

Contact us